NG25 (trihydrochloride)

NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC50: 149 nM and 21.7 nM respectively) . NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers[1][2].

Product Specifications

CAS Number

[2108554-00-1]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

MAP3K; MAP4K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ng25-trihydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC=C(CN2CCN(CC)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(OC4=C5C(NC=C5)=NC=C4)=C3.[H]Cl.[H]Cl.[H]Cl

Molecular Formula

C29H33Cl3F3N5O2

Molecular Weight

646.96

Precautions

P261-P280-P302+P352

References & Citations

[1]Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) . J Med Chem. 2015 Jan 8;58 (1) :183-96.|[2]Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737.